Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | The impact of new drugs on the lives of patients with lymphoma

Anas Younes • 3 Jun 2016
ASCO 2016
B-Cell Lymphoma Hodgkin Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma T-Cell Lymphoma

Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the cost of new drugs in lymphoma. Prof Younes argues that the impact of these drugs on the lives of young patients outweighs concerns around their cost.
Recorded at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, in Chicago, IL.

More from Anas Younes

1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals